drugset / Trial / NCT07217886
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Phase 1
Completed
24 enrolled
Shionogi
Biomedical Advanced Research and Development Authority · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
Timeline
- Start
- 2025-10-16
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-892216 | Unknown | — | Oral |